


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**THREE PRODUCTS APPROVED FOR MARKETING**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has obtained drug registration certificates from the National Medical Products Administration of China for the anti-infective drugs “Tedizolid Phosphate Tablets” and “Tedizolid Phosphate for Injection” and breast cancer drug “Palbociclib Capsules” developed by the Group.

**Tedizolid Phosphate Tablets and Tedizolid Phosphate for Injection**

Tedizolid is a second generation oxazolidinone antibiotic used for acute bacterial skin and skin structure infections (“**ABSSSI**”) in adults caused by specific sensitive bacteria. Tedizolid phosphate acts as a prodrug and is rapidly converted in vivo by phosphatase to the biologically active tedizolid, which binds to the ribosomal 50S subunit of the bacterium, thereby inhibiting protein synthesis.

ABSSSI includes cellulitis or erysipelas, skin abscesses and wound infections. Gram-positive cocci (G+ bacteria) have been the major causes of skin infections, including *Staphylococcus aureus* and *Streptococcus pyogenes*. Among these, *Staphylococcus aureus* infections are classified as methicillin-susceptible and methicillin-resistant *Staphylococcus* (“**MRSA**”) infections. The former is mainly treated with penicillins and cephalosporins, while the latter is treated with drugs including linezolid (a first-generation oxazolidinone) and vancomycin, etc.

In vitro drug sensitivity studies have shown that tedizolid phosphate is 4-16 times more active than linezolid against most Gram-positive bacteria. In vitro antibacterial studies have shown that tedizolid can also be used against MRSA, linezolid-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci. In addition, tedizolid phosphate is available in both injection and oral tablet dosage forms, which allows for easy clinical switching and reduces the length of hospital stay, thereby reducing the cost of treatment for patients.

With the widespread use of antibiotic drugs, bacterial resistance is a challenging clinical issue. The approval of two dosage forms of the Group's tedizolid phosphate products will help alleviate this problem and provide more options for patients with drug-resistant Gram-positive bacterial infections, further addressing an unmet clinical need.

### **Palbociclib Capsules**

Palbociclib is the world's first inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for marketing. It can selectively inhibit CDK4/6, restoring cell cycle control and blocking tumour cell proliferation. It is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, which shall be used in combination with an aromatase inhibitor as the initial endocrine therapy for postmenopausal women.

The Group has been conducting research and development of oncology medicines for years. The approval of Palbociclib Capsules for marketing will enrich the Group's product pipeline of drugs in the field of breast cancer and bring benefits to the treatment of breast cancer patients.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 1 March 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*